ReviewAntibiotics (Basel, Switzerland)2020
Novel Antibiotics Targeting Bacterial Replicative DNA Polymerases.
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- DnaE uses strand displacement synthesis during Okazaki fragment repair.bioRxiv : the preprint server for biology · 2026Article
- Determinants of prescribing behaviour of antibacterial drugs in Europe and use of appropriate nomenclature in the literature.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Identification of determinants of high-fidelity DNA synthesis in Mycobacterium smegmatis DnaE1 through in silico and in vivo approaches.Nucleic acids research · 2025Article
- A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens.Nature communications · 2025Article
- Natural Products with Potent Antimycobacterial Activity (2000-2024): A Review.Molecules (Basel, Switzerland) · 2025Review
- Exploring the Role of Berberine as a Molecular Disruptor in Antimicrobial Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Next Frontier: Unveiling Novel Approaches for Combating Multidrug-Resistant Bacteria.Pharmaceutical research · 2025Review
- Antioxidant capacities and in vitro anti-microbial activities of rice (Oryza sativa var Bajong) from Borneo.BMC chemistry · 2025Article
- Antimicrobial Resistance and Risk Factors of Canine Bacterial Skin Infections.Pathogens (Basel, Switzerland) · 2025Article
- A Review of Antibacterial Candidates with New Modes of Action.ACS infectious diseases · 2024Review
- How Unnatural Amino Acids in Antimicrobial Peptides Change Interactions with Lipid Model Membranes.The journal of physical chemistry. B · 2024Article
- Novel non-helical antimicrobial peptides insert into and fuse lipid model membranes.Soft matter · 2024Article
- Nutraceutical and Medicinal Importance of Marine Molluscs.Marine drugs · 2024Review
- Antimicrobial Action Mechanisms of Natural Compounds Isolated from Endophytic Microorganisms.Antibiotics (Basel, Switzerland) · 2024Review
- Metabolic Labeling: Snapshot of the Effect of Toxins on the Key Cellular Processes.Methods in molecular biology (Clifton, N.J.) · 2024Article
- BRCT Domains: Structure, Functions, and Implications in Disease-New Therapeutic Targets for Innovative Drug Discovery against Infections.Pharmaceutics · 2023Review
- Novel Helical Trp- and Arg-Rich Antimicrobial Peptides Locate Near Membrane Surfaces and Rigidify Lipid Model Membranes.Advanced nanobiomed research · 2023Article
- Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling.RSC medicinal chemistry · 2022Article
- Expression, Purification, and Biophysical Characterization of Klebsiella Pneumoniae Nicotinate Nucleotide Adenylyltransferase.The protein journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance is a worldwide problem that is an increasing threat to global health. Therefore, the development of new antibiotics that inhibit novel targets is of great urgency. Some of the most successful antibiotics inhibit RNA transcription, RNA translation, and DNA replication. Transcription and translation are inhibited by directly targeting the RNA polymerase or ribosome, respectively. DNA replication, in contrast, is inhibited indirectly through targeting of DNA gyrases, and there are currently no antibiotics that inhibit DNA replication by directly targeting the replisome. This contrasts with antiviral therapies where the viral replicases are extensively targeted. In the last two decades there has been a steady increase in the number of compounds that target the bacterial replisome. In particular a variety of inhibitors of the bacterial replicative polymerases PolC and DnaE have been described, with one of the DNA polymerase inhibitors entering clinical trials for the first time. In this review we will discuss past and current work on inhibition of DNA replication, and the potential of bacterial DNA polymerase inhibitors in particular as attractive targets for a new generation of antibiotics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.